We’re proud to share that Beckie Fenrick, PharmD, MBA—Chief Pharmacy Officer at Navion—was recently featured in The Self-Insurer, the official publication of the Self-Insurance Institute of America (SIIA).
The article, titled “Better Outcomes. Long-Term Cost Savings: The Mayo Clinic Complex Care Program,” explores innovative care models that drive improved health outcomes and sustainable cost savings. Beckie offered her insights on the value of clinical integration and how pharmacy strategies can support long-term success for self-funded plans.
Read a featured passage from the article below:
As more manufacturers continue to enter the biosimilar market, plan sponsors have unprecedented to control costs while maintaining access to the therapies members need most.
Beckie Fenrick, Pharm D, MBA, chief pharmacy officer, Navion, affirms, “Biosimilars deliver substantial market value-and at Navion, we strongly recommend that plan sponsors embrace proactive strategies to promote biosimilar adoption. By driving utilization toward clinically equivalent, lower-cost options, organizations can enhance both affordability and access across their populations.”
She says biologics are a cornerstone in treating many autoimmune conditions-yet their high costs are often a barrier to care, adding “The introduction of biosimilar has the power to reshape this landscape. Injecting meaningful price competition and driving down treatment costs for patients and plan sponsors alike. Biosimilars make advanced therapies more accessible, ensuring that cost does not stand in the way of care.”
Read the full article in The Self-Insurer Magazine to learn more about the role of pharmacy leadership in driving meaningful change across complex care programs.
